AnaptysBio - Anaptys to Announce Top-line Data from Phase 2b Trial of Rosnilimab, a PD-1 Depleter and Agonist, in Rheumatoid Arthritis on Feb. 12, 2025
About
Overview
Strategy
Senior Leadership
Board of Directors
Scientific Advisory Board
Contact
Science
Immune Cell Modulation
Listen to Short Takes on Deep Science
Anaptys Publications and Relevant Literature
Pipeline
Overview
Rosnilimab
ANB033
ANB101
Partnerships
Investors / News
Overview
News
Events
Presentations
Goverance
Stock Information
Analyst Coverage
SEC Filings
Investor FAQs
Contact
Careers
Overview
See Where We Work
Total Rewards Program Highlights
Get to Know Our Team
Join Team Anaptys!
Contact
Toggle
Home
Anaptys to Announce Top-line Data from Phase 2b Trial of Rosnilimab, a PD-1 Depleter and Agonist, in Rheumatoid Arthritis on Feb. 12, 2025
Anaptys to Announce Top-line Data from Phase 2b Trial of Rosnilimab, a PD-1 Depleter and Agonist, in Rheumatoid Arthritis on Feb. 12, 2025
Home
Anaptys to Present at the 43rd Annual J.P. Morgan Healthcare Conference
Anaptys to Present at the 43rd Annual J.P. Morgan Healthcare Conference
Home
Anaptys Announces Participation in November and December Investor Conferences
Anaptys Announces Participation in November and December Investor Conferences
Home
Anaptys to Present at TD Cowen’s 44th Annual Health Care Conference and 2024 AAD Annual Meeting
Anaptys to Present at TD Cowen’s 44th Annual Health Care Conference and 2024 AAD Annual Meeting
Home
Anaptys to Present at Guggenheim’s 6th Annual Biotechnology Conference
Anaptys to Present at Guggenheim’s 6th Annual Biotechnology Conference
Home
Anaptys Announces Participation in November Investor Conferences
Anaptys Announces Participation in November Investor Conferences
Home
Anaptys to Present Phase 1 Data on ANB032, its BTLA Agonist Antibody, at the 32nd EADV Congress
Anaptys to Present Phase 1 Data on ANB032, its BTLA Agonist Antibody, at the 32nd EADV Congress
Home
Anaptys to Provide Overview of Rosnilimab, a PD-1 Agonist, at Virtual R&D Event on Wednesday, Oct. 25
Anaptys to Provide Overview of Rosnilimab, a PD-1 Agonist, at Virtual R&D Event on Wednesday, Oct. 25